European Heart Journal Advance Access originally published online on April 25, 2008
European Heart Journal 2008 29(14):1753-1760; doi:10.1093/eurheartj/ehn166
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease
Department of Cardiology, Karolinska University Hospital, Stockholm SE-171 76, Sweden
Received 14 May 2007; revised 1 April 2008; accepted 4 April 2008; online publish-ahead-of-print 25 April 2008.
* Corresponding author. Tel: +46 8 51770807, Fax: +46 8 311044, Email: magnus.settergren{at}karolinska.se
See page 1711 for the editorial comment on this article (doi:10.1093/eurheartj/ehn243)
Aims: The importance of pleiotropic effects of statins on endothelial function and inflammatory markers was investigated in patients with dysglycaemia and coronary artery disease (CAD).
Methods and results: Thirty-nine patients were randomized to simvastatin 80 mg daily (S80; n = 20) or ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10; n = 19) for 6 weeks, aiming at similar cholesterol reduction. Endothelial function, evaluated by brachial artery flow-mediated vasodilatation (FMD) and the effect of endothelin receptor blockade, serum lipids, and inflammatory markers were evaluated at baseline and follow-up. At follow-up, low-density lipoprotein cholesterol decreased from 3.1 (2.8–3.4) (median and quartiles) to 1.5 mmol/L (1.4–1.7) and from 3.0 (2.5–3.4) to 1.3 mmol/L (1.1–1.8), in the S80 and E10/S10 groups, respectively. In the entire study group, FMD increased from 4.3% (3.4–6.1) at baseline to 5.5% (3.4–6.6) at follow-up, while C-reactive protein decreased from 3.1 (1.7–7.6) to 2.3 mg/L (0.9–6.5). The changes in FMD and C-reactive protein from baseline to follow-up were not significantly different between patients on S80 and E10/S10 groups. Endothelin blockade enhanced endothelium-dependent vasodilatation both at baseline and follow-up.
Conclusion: Lipid lowering is more important than pleiotropic effects of statins for improvement in endothelial function and inflammatory markers in patients with dysglycaemia and CAD.
Key Words: Statins Pleiotropic effects Ezetimibe Endothelial function Type 2 diabetes
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Vascular form and function: two mechanisms for cardiovascular prevention
- Scott Kinlay
EHJ 2008 29: 1711-1713.[Extract] [FREE Full Text]
This article has been cited by other articles:
![]() |
J. Westerink and F. L.J. Visseren Letter by Westerink and Visseren Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation" Circulation, September 1, 2009; 120(9): e66 - e66. [Full Text] [PDF] |
||||
![]() |
M. Settergren, L. Ryden, and J. Pernow Letter by Settergren et al Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation" Circulation, September 1, 2009; 120(9): e68 - e68. [Full Text] [PDF] |
||||
![]() |
P.-Y. Liu, J. K. Liao, Y.-W. Liu, L.-J. Lin, and J.-H. Chen Response to Letters Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation" Circulation, September 1, 2009; 120(9): e69 - e70. [Full Text] [PDF] |
||||
![]() |
Z. L. S. Brookes, C. C. McGown, and C. S. Reilly Statins for all: the new premed? Br. J. Anaesth., July 1, 2009; 103(1): 99 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Al Badarin, I. J. Kullo, S. L. Kopecky, and R. J. Thomas Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out? Mayo Clin. Proc., April 1, 2009; 84(4): 353 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Napoli, V. Apuzzi, G. Bosso, C. D'Anna, A. De Sena, C. Pirozzi, A. Marano, G. A. Lupoli, G. Cudemo, U. Oliviero, et al. Recombinant Human Thyrotropin Enhances Endothelial-Mediated Vasodilation of Conduit Arteries J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 1012 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Y. Liu, Y.-W. Liu, L.-J. Lin, J.-H. Chen, and J. K. Liao Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation Circulation, January 6, 2009; 119(1): 131 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kinlay Vascular form and function: two mechanisms for cardiovascular prevention Eur. Heart J., July 2, 2008; 29(14): 1711 - 1713. [Full Text] [PDF] |
||||




